Medicamen Biotech Ltd. Hits Lower Circuit on BSE, 24 September 2026

On 24 September 2026, Medicamen Biotech Ltd. hit the lower circuit on BSE at Rs 307.75, a 4.99% negative move from the previous close of Rs 323.9. The company's market cap stood at Rs 439.3 crore. The lower circuit price for the session was Rs 307.75.

The move was driven by selling pressure against the exchange-defined price band. At the time of writing the stock was locked at its lower circuit level, which makes the session worth noting for short-term market participants.

Key Takeaways

• Medicamen Biotech Ltd. hit the lower circuit on BSE at Rs 307.75 on 24 September 2026.
• The session move was -4.99% against a previous close of Rs 323.9.
• Market capitalisation stood at Rs 439.3 crore with a PE ratio of 40.57.
• No official company announcement or verified catalyst was confirmed at the time of writing.
• A price band is an exchange trading rule, not a view on the company or a recommendation.

Key Market Data

Metric	Value
Stock	Medicamen Biotech Ltd.
Current Price / LTP	Rs 307.75
Day Move	-4.99%
Previous Close	Rs 323.9
Day Open	Rs 320
Day High	Rs 325
Day Low	Rs 307.75
Lower Circuit Price	Rs 307.75
Lower Circuit Limit	Rs 307.75
Market Cap	Rs 439.3 crore
Selected Exchange	BSE
PE Ratio	40.57

All figures above are as of 24 September 2026, sourced from Univest market data for the BSE listing. Only fields present in the source for this session are shown.

Price Action and Trading Activity

Medicamen Biotech Ltd. opened at Rs 320 on BSE, compared with a previous close of Rs 323.9. During the session, the stock traded between Rs 307.75 and Rs 325 before touching the lower circuit price of Rs 307.75.

The absolute day change was Rs 16.15, while the percentage move was -4.99%. The event figures are kept to a single exchange so the numbers stay comparable.

The selected exchange matters because price bands, day range and previous-close values can differ across exchanges. This article uses BSE consistently for the event table and narrative. The stated lower circuit limit for the session was Rs 307.75, which is the level the price reached.

Why Medicamen Biotech Ltd. Hit Lower Circuit

Medicamen Biotech Ltd. hit the lower circuit after selling pressure pushed the stock to its exchange-defined price band. No official company announcement or verified external catalyst was confirmed at the time of writing, so the move should be read primarily through price action and market sentiment.

Because no verified catalyst was available, this article does not attribute the move to earnings, corporate action, sector news, or market rumours. If a confirmed announcement becomes available later, it should be added as a separate update.

Within the session the stock reached the lower circuit level of Rs 307.75.

What the Lower Circuit Means

A lower circuit is the minimum price level a stock is allowed to reach during a trading session under the applicable exchange price band. For Medicamen Biotech Ltd., the captured lower circuit price was Rs 307.75 on 24 September 2026.

The circuit mechanism is meant to slow extreme price movement and keep trading orderly. It is a market-structure fact, not a return forecast. In this article, the lower circuit explains what happened in the session and where the price band was reached.

Medicamen Biotech Ltd. Fundamentals and Valuation

Available market data gives a fuller picture than price action alone. For Medicamen Biotech Ltd., PE ratio was 40.57, PB ratio was 1.62, book value was Rs 199.52, EPS was 7.98, ROE was 3.23%, ROCE was 5.77%, dividend yield was 0.31% and debt-to-assets ratio was 0.16, on a market cap of Rs 439.3 crore. These are available financial indicators and should not be read as a buy, sell, or hold view.

A PB ratio above 1 means the market price was above the reported book value per share. That premium can reflect growth expectations, asset quality, or simply thin trading in a smaller counter.

For investors tracking lower circuit moves, these metrics help separate the price event from the broader financial profile. A sharp one-day move can attract attention, but valuation and return ratios still need to be reviewed separately.

Peer and Sector Context

Medicamen Biotech Ltd. belongs to the Pharmaceuticals & Drugs industry within the Healthcare sector. The peer table below uses available companies from the same sector or industry to give broader valuation context.

Peer Company	Market Cap	PE	PB	ROE
Hikal Ltd.	Rs 2809.41 crore	-	2.41	-
Dishman Carbogen Amcis Ltd.	Rs 2663.74 crore	168.23	0.41	-
Sakar Healthcare Ltd.	Rs 2644.18 crore	71.66	7.73	-
Panacea Biotec Ltd.	Rs 2350.19 crore	-	2.79	-
Indoco Remedies Ltd.	Rs 2347.74 crore	412.58	2.33	-

A dash in the PE column means no PE ratio was carried for that company in the source data, which happens when reported earnings are negative or have not been refreshed. Those companies are left out of the average below rather than counted as zero.

Several of these peers are far larger by market capitalisation than Medicamen Biotech Ltd. Size differences change liquidity and cost of capital, so the table is sector context rather than a like-for-like ranking.

Medicamen Biotech Ltd.'s PE ratio was 40.57, compared with an available peer/sector PE average of 51.81, calculated from the 3 peer companies that had a PE on record. This comparison is a valuation reference point, not a recommendation.

Technical and Ownership Snapshot

The technical snapshot adds context: RSI was 73.38, the 50-day moving average was 280.26 and the 200-day moving average was 269.23.

Worth flagging: the RSI reading sits on the opposite side of neutral to the day move and the last traded price and the 50-day average point in different directions. Indicator values in the dataset can lag the live session, so they should be checked against a live chart before being relied on.

Shareholding details were not available in the latest market dataset, so no conclusion is drawn about promoter, institutional, or public-shareholder activity.

What Readers Should Know

The main confirmed fact is that Medicamen Biotech Ltd. hit the lower circuit on BSE at Rs 307.75 on 24 September 2026, with a 4.99% day move.

The practical limitation after a lower-circuit session is execution. Sellers queue at the band with few buyers, so exiting at the quoted price may not be possible. The other limitation is that no official catalyst was confirmed at the time of writing.

Readers should treat lower circuit events as market updates, not standalone investment conclusions. The price band shows heavy near-term selling pressure, but follow-up analysis should consider business fundamentals, valuation, liquidity, risk, and confirmed company disclosures.

Frequently Asked Questions

Why did Medicamen Biotech Ltd. hit lower circuit on 24 September 2026?

The stock reached its lower price band after selling pressure during the session. No official company announcement or verified external catalyst was confirmed at the time of writing.

What was Medicamen Biotech Ltd. share price on 24 September 2026?

The last traded price used in this article was Rs 307.75 on BSE. That price matched the lower circuit price captured for the event.

What was the lower circuit price for Medicamen Biotech Ltd.?

The lower circuit price was Rs 307.75. The stated exchange lower circuit limit was Rs 307.75. The event numbers in this article are aligned to BSE.

What is Medicamen Biotech Ltd.'s market cap and PE ratio?

Medicamen Biotech Ltd.'s market cap was Rs 439.3 crore. PE ratio was 40.57.

Which exchange and data source were used?

The selected exchange was BSE. The article uses Univest market data available at the time of generation, captured on 24 September 2026.

Does hitting a lower circuit mean Medicamen Biotech Ltd. is a buy or a sell?

No. A circuit is an exchange price-band rule that caps how far a stock can move in a single session. It carries no view on valuation or business quality and is not a recommendation. Any decision should rest on fundamentals, valuation, liquidity and your own risk tolerance.

Can you buy or sell Medicamen Biotech Ltd. shares when the stock is at the lower circuit?

It is usually difficult. At the lower circuit, sell orders queue up with few buyers, so exiting at the quoted price may not be possible. Orders can stay unfilled until buying interest returns.

What happens the next trading session after a lower circuit?

There is no fixed outcome. The band resets each session, so the stock can open freely, hit the same band again, or reverse. The exchange can also revise the applicable band width. The useful signals to watch are whether the company files any disclosure explaining the move.

What is the lower circuit limit set at for Indian stocks?

Exchange price bands are commonly set at 2%, 5%, 10% or 20% depending on the security, and the applicable band can be revised by the exchange. For Medicamen Biotech Ltd. the stated limit was Rs 307.75. For this session, Medicamen Biotech Ltd. moved 4.99%.

Footer Disclosure